Symbiotec Pharmalab Limited (SYMBIOTEC)
சுருக்கம்
Symbiotec Pharmalab Limited closed at ₹1,642.40 on 12 Nov 2026. Data as of 12 Nov 2026.
விலை
- சந்தை மதிப்பு
- ₹10,386 கோடி
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 5 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 நவ. 2026
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 29.85% எதிர் சராசரி 35.09%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 1.1×
- விலை வரம்பு
- 1 band close in ~20 sessions
- இன்சைடர் வர்த்தகம்
- 90 நாட்களில் 16 அறிவிப்பு; சந்தையில் நிகர விற்பனை ₹11.9 கோடி
பங்கு உரிமைசெப். 2026
- புரமோட்டர்கள்
- 33.28%
- FII-கள்
- 3.79%
- DIIs
- 33.17%
செப்டம்பர் 2026 உடன் முடிவடைந்த காலாண்டுக்கான பங்குதாரர் விவரம்; சதவீதப் புள்ளிகளில் மாற்றங்கள்.
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Symbiotec Pharmalab Limited reported Q2 FY27 results on 5 Nov 2026: revenue ₹280 Cr, and net profit ₹51.7 Cr; the operating margin was 32.7%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹280 | — | +28.3% |
| செயல்பாட்டு லாபம் | ₹91.5 | — | +102.5% |
| நிகர லாபம் | ₹51.7 | — | +267.8% |
| EPS (₹) | 8.20 | — | +266.1% |
| செயல்பாட்டு லாப வரம்பு | 32.7% | — | — |
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹64.0 கோடி லாபத்தில், ₹63.9 கோடி (100%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
முடிவுகள் வெளியானதிலிருந்து பங்கு விலை: +29.2% (அறிவிப்புக்கு முந்தைய முடிவு விலை முதல் சமீபத்திய முடிவு விலை வரை).
SYMBIOTEC டெலிவரி சதவீதம்
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 29.85% of the SYMBIOTEC shares traded on NSE were taken to delivery, against the stock's own 20-session average of 35.09%. That is close to its usual level. It closed at a price band (circuit) on 1 session in about the last 20.
கடந்த 5 அமர்வுகளில் டெலிவரி: 46.6% · 17.2% · 18.0% · 27.1% · 29.9%
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Symbiotec Pharmalab reported 43% YoY revenue growth and 88% EBITDA growth for Q2 FY27, driven by steady API demand and commercial milestone inflows. In its complex injectables division, the company recognized ₹53 crore in development and regulatory milestones under a long-term US partnership targeting a $300 million market. In fermentation CDMO, it confirmed a manufacturing pact with a European alternate protein firm, scaling from 100 KL to 250 KL at Ujjain, alongside existing 10-year and 5-year take-or-pay contracts. Management noted its backward-integrated steroid API model shielded gross margins from rising solvent and logistics costs, limiting margin impact to 2-3%.
- Q2 FY27 reported revenues grew 43% YoY, while reported EBITDA expanded by 88% YoY.
- Recognized ₹53 crore in milestone revenue in Q2 under a long-term US partnership for 2 dual-chamber vial (DCV) products.
- US addressable market for the two DCV products is estimated at around USD 300 million annually.
- Signed manufacturing pact with a European alternate protein firm to scale fermentation from 100 KL to 250 KL at Ujjain.
- Commercial batches for the 10-year US alternate protein take-or-pay contract expected in Q1 FY28.
Symbiotec Pharmalab has signed a 10-year, take-or-pay contract development and manufacturing agreement (CDMO) with an unnamed European alternative protein innovator. Production will take place at its biomanufacturing campus in Ujjain using four 100 kL fermenters, with plans to build a dedicated facility offering several hundred thousand litres of fermentation capacity. The deal also reserves future expansion options extending into millions of litres. Financial consideration and exact contract values were not disclosed due to confidentiality obligations.
- 10-year take-or-pay CDMO agreement signed with a European alternative protein innovator
- Production based at Ujjain biomanufacturing campus featuring four 100 kilolitre (kL) fermenters
- Planned addition of a new dedicated plant with several hundred thousand litres of fermentation capacity
- Contracted future expansion options reserved to scale into millions of litres
- Financial consideration not disclosed due to confidentiality clauses
Symbiotec Pharmalab reported strong Q2FY27 consolidated performance with revenue rising 43% YoY to ₹280 crore and consolidated PAT surging 169% YoY to ₹52 crore. Growth was aided by the core API business (revenue up 16% YoY to ₹227 crore with ~30% EBITDA margins) and milestone-based revenue of ₹53 crore from Complex Injectables. The company outlined an aggressive cumulative gross capex plan of ~₹1,672 crore by end-FY27, of which ~₹1,000 crore (61%) is targeted toward new revenue-generating lines. Net debt as of September 30, 2026, stood at ~₹314 crore.
- Q2FY27 consolidated revenue grew 43% YoY to ₹280 crore, with consolidated PAT up 169% YoY to ₹52 crore.
- API business delivered ₹227 crore operating revenue (up 16% YoY) with steady ~30% EBITDA margins.
- Recognized milestone-based revenue of ₹53 crore in Q2FY27 from a US licensing agreement for two DCV complex injectable products.
- Estimated total gross capex of ~₹1,672 crore by end of FY27, with ₹113 crore invested in H1FY27.
- Reported consolidated net debt of ~₹314 crore as of September 30, 2026.
Symbiotec Pharmalab reported strong Q2FY27 performance with consolidated revenue growing 43% YoY to ₹280 crore and PAT surging 169% YoY to ₹52 crore. Performance was aided by core API sales rising 16% to ₹227 crore and milestone revenue recognition of ₹53 crore from a US DCV licensing pact. Out of its ₹1,509 crore gross capex as of September 2026, over ₹1,000 crore (61%) is deployed into new ventures—Complex Injectables and CDMO—expected to start commercial revenue in the next 6–12 months.
- Q2FY27 consolidated revenue rose 43% YoY to ₹280 crore, with reported EBITDA up 82% to ₹92 crore (32.7% margin).
- Consolidated PAT expanded 169% YoY to ₹52 crore in Q2FY27 vs ₹19 crore in Q2FY26.
- Recognized ₹53 crore milestone revenue in Q2 from a US distribution licensing deal for two Dual Chamber Vial (DCV) products.
- Gross capex stood at ₹1,509 crore as of Sep 30, 2026, with ₹1,000+ crore invested in new businesses slated to generate revenue in 6–12 months.
- In advanced stages to execute a 10-year take-or-pay agreement with a European alternative protein firm for CDMO capacity.
Symbiotec Pharmalab reported its Q2 FY27 (ended September 30, 2026) consolidated results, with revenue from operations growing 43.2% YoY to ₹2,799.28 million (₹279.93 cr) compared to ₹1,955.15 million in Q2 FY26. Consolidated net profit for the quarter rose sharply to ₹517.18 million (₹51.72 cr), up from ₹192.18 million in the year-ago period and ₹140.61 million in Q1 FY27. Diluted EPS for the quarter reached ₹8.20 versus ₹3.43 in Q2 FY26. The company also confirmed full utilisation of ₹1,420 million in net IPO proceeds towards debt prepayment and general corporate purposes, leaving just ₹0.25 million unutilised.
- Revenue from operations grew 43.2% YoY to ₹2,799.28 million in Q2 from ₹1,955.15 million in Q2 FY26
- Consolidated net profit surged to ₹517.18 million vs ₹192.18 million YoY and ₹140.61 million QoQ
- Quarterly diluted EPS increased to ₹8.20 compared to ₹3.43 in Q2 FY26 and ₹2.24 in Q1 FY27
- Company completed IPO raising ₹1,500 million fresh issue, utilizing ₹1,420 million towards debt repayment and corporate purposes
Symbiotec Pharmalab Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate issued by Registrar and Share Transfer Agent MUFG Intime India Private Limited confirms the dematerialisation, mutilation, and cancellation of security certificates within prescribed timelines. This is a standard quarterly administrative filing with zero impact on operational or financial metrics.
- Compliance certificate filed pursuant to Regulation 74(5) of SEBI Regulations, 2018
- Covers the quarter ended September 30, 2026
- வெளியிட்டவர்: RTA MUFG Intime India Private Limited; தேதி அக்டோபர் 03, 2026
Symbiotec Pharmalab's wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive strategic commercialization agreement with an undisclosed leading global pharmaceutical company for two Dual Chamber Vial (DCV) injectable products in the United States. Knovea will handle development, regulatory filings, manufacturing, and supply, while the partner manages US distribution. The agreement includes milestone payments across development and regulatory stages, along with profit-sharing post-launch. The two target products address an estimated US addressable market of approximately $288 million, where currently only the innovator offers a DCV presentation.
- Exclusive US distribution agreement signed for 2 Dual Chamber Vial (DCV) injectable products
- Target products address an estimated US market size of approximately US$288 million
- Deal structured with development/regulatory milestone payments plus post-launch profit sharing
- Knovea responsible for development, US regulatory filings, manufacturing, and commercial supply
Symbiotec Pharmalab Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Pithampur (SEZ), Madhya Pradesh. The regulatory inspection was conducted between August 10, 2026, and August 14, 2026. The U.S. FDA classified the inspection status as Voluntary Action Indicated (VAI), indicating successful closure of the inspection without critical regulatory roadblocks. This resolution ensures continuity of regulatory compliance for U.S. market supplies from this site.
- Received Establishment Inspection Report (EIR) from the U.S. FDA on September 29, 2026
- Facility inspected: Pithampur (SEZ), Madhya Pradesh, India
- Inspection period: August 10, 2026 to August 14, 2026
- Assigned Voluntary Action Indicated (VAI) classification, concluding the regulatory audit
Symbiotec Pharmalab has submitted the transcript for its Q1 FY27 earnings conference call held on September 22, 2026. The management highlighted that over 90% of its current fiscal year revenues come from its core steroid and hormone API business, which is expected to grow in high single digits. The company is diversifying into high-margin biotech fermentation CDMO and complex injectables platforms, aiming for these new verticals to constitute more than 50% of revenue in 5-6 years. Furthermore, nearly 70% of FY26 revenues were derived from relationships older than 7 years across 200+ global customers.
- Over 90% of current fiscal year annual revenue is estimated to come from the steroid hormones API business.
- Nearly 70% of FY26 revenues came from clients with customer relationships exceeding 7 years.
- Portfolio supported by 44 US DMFs and 25 European CEPs across 60 corticosteroid and hormone APIs.
- Long-term guidance envisions new CDMO and injectables verticals reducing the core API revenue share to less than 50% in 5-6 years.
- Industry peer benchmark EBITDA margins for complex CMO and injectables cited at above 35% with gross margins over 70%.
Symbiotec Pharmalab reported its first quarterly results as a listed entity for Q1FY27, with consolidated revenue rising 7.4% YoY to ₹218.2 crore from ₹203.2 crore. Consolidated EBITDA declined 22% YoY to ₹45.2 crore, and consolidated PAT dropped 52.8% to ₹14.1 crore, largely due to ₹35 crore in drag from pre-operating opex (₹23 crore) and depreciation (₹12 crore) on new businesses. Meanwhile, core API business operating revenue grew 6% YoY to ₹215.3 crore with steady EBITDA margins of ~30%. The company has planned a total gross capex of approx. ₹1,666 crore by end FY27, with revenue commercialization expected in the next 6-12 months.
- Consolidated revenue up 7.4% YoY to ₹218.2 cr, while consolidated PAT fell 52.8% YoY to ₹14.1 cr
- Pre-operating drag of ₹23 cr opex and ₹12 cr depreciation impacted consolidated profitability
- Core API operating revenue stood at ₹215.3 cr with EBITDA of ₹65.8 cr (~30% margin)
- Total estimated gross capex of approx. ₹1,666 cr by end-FY27 (~₹1,000 cr invested in new ventures)
- Net debt reduced from ~₹398 cr (as of June 30, 2026) to ~₹326 cr post-IPO proceeds on Sept 20, 2026
Symbiotec Pharmalab reported its unaudited financial results for the quarter ended June 30, 2026, marking its first post-IPO quarterly reporting following its September 1, 2026 stock exchange listing. For Q1 FY27, the company registered a standalone net loss of ₹156.90 million compared to a profit of ₹445.05 million in Q1 FY26. Total standalone expenses stood at ₹1,818.97 million against ₹1,663.29 million in the year-ago period. The company completed an IPO raising ₹1,500.00 million via fresh issue and ₹16,070.00 million through an offer for sale at an issue price of ₹988 per share.
- Standalone net loss stood at ₹156.90 million for Q1 FY27 compared to a net profit of ₹445.05 million in Q1 FY26
- Basic and diluted EPS dropped to negative ₹2.73 and ₹2.71 respectively for the quarter ended June 30, 2026
- Completed IPO of 17,786,442 equity shares at ₹988 per share, consisting of a ₹1,500.00 million fresh issue and ₹16,070.00 million OFS
- Total standalone expenses reached ₹1,818.97 million for Q1 FY27 versus ₹1,663.29 million in Q1 FY26
Symbiotec Pharmalab Limited released its financial results for the quarter ended June 30, 2026, marking its first quarterly reporting under SEBI LODR post-listing. Subsequent to the quarter-end, the company listed on NSE and BSE on September 1, 2026, following an IPO of 1,77,86,442 equity shares at Rs 988 per share, which included a fresh issue of Rs 1,500.00 million and an OFS of Rs 16,070.00 million. For comparison, FY26 consolidated revenue from operations stood at Rs 8,451.65 million with net profit of Rs 1,158.28 million. SRBC & CO LLP issued an unmodified limited review report on the consolidated results.
- Completed IPO of 1,77,86,442 shares at Rs 988 per share, listing on NSE/BSE on September 1, 2026
- IPO fresh issue aggregated to Rs 1,500.00 million, while OFS aggregated to Rs 16,070.00 million
- Consolidated FY26 full-year revenue stood at Rs 8,451.65 million and net profit at Rs 1,158.28 million
- Statutory auditor SRBC & CO LLP issued an unmodified limited review report
Symbiotec Pharmalab Limited submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) pursuant to Regulation 8(2) of the SEBI PIT Regulations. The filing follows an earlier intimation dated September 01, 2026. The policy document outlines procedures for uniform dissemination of price-sensitive data, handling of legitimate business information sharing, and appointment of the Chief Investor Relations Officer (CIRO). This is a routine regulatory compliance filing with no impact on business operations or financials.
- Filing submitted under Regulation 8(2) of SEBI (PIT) Regulations, 2015 on September 03, 2026
- Follows prior intimation dated September 01, 2026
- Fair Disclosure Policy original effective date noted as December 15, 2025
- Establishes protocols for UPSI dissemination and CIRO reporting lines to the CFO
Symbiotec Pharmalab Limited has submitted an intimation under Regulation 30(5) of the SEBI LODR Regulations, 2015. The company has authorized three Key Managerial Personnel (KMPs) to determine the materiality of events or information and make stock exchange disclosures. The authorized personnel comprise CMD Anil Satwani, CFO Raghavender Ramachandran, and CS Salil Jain.
- Disclosure filed pursuant to Regulation 30(5) of SEBI LODR Regulations, 2015 on September 01, 2026
- Authorized 3 Key Managerial Personnel to evaluate event materiality and stock exchange disclosures
- Designated KMPs include Chairman & MD Anil Satwani, CFO Raghavender Ramachandran, and CS Salil Jain
Symbiotec Pharmalab Limited has submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to stock exchanges on September 01, 2026. The submission is made pursuant to Regulation 8(2) framed under Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is a standard regulatory compliance filing with no impact on operations or financials.
- Filing submitted under Regulation 8(2) of SEBI PIT Regulations, 2015
- Adoption of Code of Practices and Procedures for Fair Disclosure of UPSI
- Intimation dated September 01, 2026 submitted to BSE (544889) and NSE (SYMBIOTEC)
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
